Results 181 to 190 of about 31,601 (273)

Evaluation of a New Potential Bevacizumab Biosimilar in Corneal Neovascularization. [PDF]

Turk J Ophthalmol
Özgür A, Yeşilırmak N, İnan MA, Bağrıaçık EÜ, Özmen MC.   +4 more
europepmc   +1 more source

Issue Information

Journal of Diabetes Investigation, Volume 17, Issue 1, Page 1-4, January 2026.
wiley   +1 more source

Savings from biosimilars and Medicare formulary access. [PDF]

Health Aff Sch
Axelsen K, Courmier D, Bai G, Maini L.
europepmc   +1 more source

Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico

, 2018
Arturo Mayoral-Zavala, A. Esquivel-Aguilar, C.M. del Real-Calzada, Ylse Gutiérrez-Grobe, J. Ramos-García, J.L. Rocha-Ramírez, Moisés F. Rojas-Illañes, B. Rubio-Martínez, Xochiquétzal Sánchez-Chávez, Jesús K. Yamamoto‐Furusho   +9 more
openalex   +1 more source

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis [PDF]

, 2016
Radan Keil, Martin Wasserbauer, Zdena Zádorová, Jan Hajer, Pavel Drastich, Pavel Wohl, Marek Beneš, Martina Bojková, Pavel Svoboda, M Konečný, Přemysl Falt, Tomáš Vaňásek, Martin Pešta, František Pešek, Luděk Bouchner, Jana Koželuhová, Aleš Novotný, Lucie Bartůsková, Julius Špičák   +18 more
openalex   +1 more source

Safety outcomes in 2132 Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111) in routine care. [PDF]

Ther Adv Musculoskelet Dis
Nabi H, Jensen KY, Westermann R, Hendricks O, Jensen DV, Loft AG, Just SA, Pedersen JK, Danebod K, Munk HL, Kristensen S, Colic A, Thygesen PH, Ammitzbøll M, Chrysidis S, Mehnert F, Steen Krogh N, Hetland ML, Glintborg B.   +18 more
europepmc   +1 more source

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data [PDF]

, 2019
María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdés Delgado, Luisa Castro Laria, Belén Maldonado Pérez, Raúl Perea Amarillo, Vicente Merino Bohórquez, Ángel Caunedo Álvarez, Ángel Vilches‐Arenas, Federico Argüelles‐Arias   +9 more
openalex   +1 more source

Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis. [PDF]

Saudi Pharm J
Shan H, Guo Z, Ye X, Du Q, Liu J, Wang M.   +5 more
europepmc   +1 more source

Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names [PDF]

, 2015

core   +1 more source

Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey

, 2021
Isabelle Arnet, Melina Verbeek, Anna Birna Almarsdóttir, Liese Barbier, Rhonda Clifford, Christiane Eickhoff, Kurt E. Hersberger, Isabelle Huys, Kenneth Lee, Kritsanee Saramunee, Martin Schulz, David P. Zgarrick, Kati Sarnola   +12 more
openalex   +1 more source